Germany · Delayed Price · Currency is EUR Heidelberg Pharma AG Earnings Call Transcripts
Fiscal Year 2025
-
Strategic refocus on HDP-101 after a major partner delay led to cost reductions and a 75% workforce cut. Cash runway now extends to mid-2027, with promising clinical results for HDP-101 and new partnerships advancing. FY2025 saw higher R&D costs and a net loss of EUR 42.3 million.
-
HDP-101, a novel ADC for multiple myeloma, shows strong efficacy and a favorable safety profile in heavily pretreated patients, with rapid and deep responses in the highest dose cohort. Fast track designation was granted, and development plans target both post-BCMA and high-risk populations.
-
Announced a strategic refocus on HDP-101 and major cost reductions after a delayed $70M milestone payment tied to TLX250-CDx FDA approval. HDP-101 shows strong clinical promise, while other programs are paused or scaled back. Cash runway is extended to mid-2026.
-
HDP-101, an amanitin-based ADC targeting BCMA, shows strong efficacy and a favorable safety profile in heavily pretreated multiple myeloma patients, including durable complete remissions. Dose optimization has mitigated early thrombocytopenia, and phase II development is imminent.
-
A novel ADC platform using amanitin shows strong preclinical and early clinical efficacy in drug-resistant cancers, with a lead program in multiple myeloma achieving durable remissions and a favorable safety profile. Financially, the company is well-funded through royalty deals and strategic partnerships, with key milestones expected in 2024 and 2025.
Fiscal Year 2024
-
Clinical pipeline advanced with strong HDP101 data and extended cash runway into 2027 via royalty deals. FY2024 saw reduced losses and improved cash flow, with key regulatory milestones expected in 2025.